Endocyte Revenue and Competitors

Claim your profile

West Lafayette, IN USA

Location

$114.3M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Endocyte's estimated annual revenue is currently $2.1M per year.(i)
  • Endocyte received $101.8M in venture funding in April 2014.
  • Endocyte's estimated revenue per employee is $100,500
  • Endocyte's total funding is $114.3M.

Employee Data

  • Endocyte has 21 Employees.(i)
  • Endocyte grew their employee count by -12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$38.6M19221%N/AN/A
#2
$539.3M26837%N/AN/A
#3
$2.2M22-19%$1.5MN/A
#4
$2.8M34-6%N/AN/A
#5
$3M36-10%N/AN/A
#6
$260.5M129622%N/AN/A
#7
$3.3M4018%N/AN/A
#8
$27760M438844%N/AN/A
#9
$2.6M13-48%N/AN/A
#10
$57.7M2876%N/AN/A

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

$114.3M

Total Funding

21

Number of Employees

$2.1M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Endocyte News

2022-04-17 - Evolving Role of Prostate-Specific Membrane Antigen ...

Consulting or Advisory Role: Bayer, Endocyte, Advanced Accelerator Applications, ORIC Pharmaceuticals, Johnson & Johnson, Curium Pharma,...

2022-03-22 - Novartis wins FDA OK for radiopharmaceutical drug, cashing ...

Novartis wins FDA OK for radiopharmaceutical drug, cashing in on Endocyte deal. Published March 24, 2022. By Kristin Jensen. Novartis...

2019-09-09 - Global Cancer Tubulin Inhibitors Market Volume Analysis ...

Major Players in Cancer Tubulin Inhibitors Market are Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...

2019-08-20 - Global Cancer Tubulin Inhibitors Market 2019 – Abraxis ...

The major player of the Cancer Tubulin Inhibitors market (Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, ...

2019-08-13 - iTeos Therapeutics Announces Appointment of Matthew Call ...

During his 16 year tenure at Endocyte, he had responsibility for all business development and strategic transactions and led a variety of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.5M2124%N/A
#2
$3.5M28N/AN/A
#3
$5.7M327%N/A
#4
$4.3M3210%N/A
#5
$3.6M327%N/A

Endocyte Funding

DateAmountRoundLead InvestorsReference
2004-11-22$3.5MUndisclosedArticle
2004-12-07$23.0MC-2Burrill and CompanyArticle
2006-11-14$30.0MDArticle
2007-03-26$15.0MC3Article
2008-02-06$15.0MUndisclosedOxford Finance Corp, GE Healthcare Financial ServicArticle
2009-10-19$26.0MCSanderling Ventures, Burrill & CompanyArticle
2010-09-01$15.0MUndisclosedMidCap Financial, Silicon Valley BankArticle
2011-08-04$66.8MUndisclosedArticle
2014-03-27$UndisclosedUndisclosedCredit Suisse Securities (USA) LLCArticle
2014-04-04$101.8MUndisclosedArticle